Urogen Pharma (URGN)

Urogen Pharma (URGN) Income Statement


Urogen Pharma Income Statement

Last quarter (Q3 2022), Urogen Pharma's total revenue was $16.10M, an increase of 41.81% from the same quarter last year. In Q3, Urogen Pharma's net income was $-25.83M. See Urogen Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
$ 62.44M$ 48.04M$ 11.80M$ 18.00K$ 1.13M$ 8.16M
Cost of Revenue
$ 6.98M$ 5.16M$ 1.01M$ 0.00$ 1.80M$ 600.00K
Gross Profit
$ 55.46M$ 42.88M$ 10.79M$ 18.00K$ -675.00K$ 7.56M
Operating Expense
$ 134.13M$ 135.18M$ 137.53M$ 109.50M$ 76.50M$ 27.51M
Operating Income
$ -78.67M$ -92.29M$ -126.74M$ -109.48M$ -77.18M$ -19.95M
Net Non Operating Interest Income Expense
$ -4.67M$ 212.00K$ 1.63M$ 4.33M$ 1.87M$ 125.00K
Other Income Expense
$ -23.82M$ -17.29M-$ -284.00K$ -224.00K$ -156.00K
Pretax Income
$ -107.16M$ -109.37M$ -125.11M$ -105.15M$ -75.53M$ -19.98M
Tax Provision
$ 2.20M$ 1.45M$ 3.37M$ 0.00$ 125.00K$ 19.00K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -109.37M$ -110.82M$ -128.48M$ -105.15M$ -75.66M$ -20.00M
Basic EPS
$ -4.83$ -4.96$ -5.90$ -5.12$ -4.80$ -2.14
Diluted EPS
$ -4.83$ -4.96$ -5.90$ -5.12$ -4.80$ -2.14
Basic Average Shares
$ 90.57M$ 22.35M$ 21.78M$ 20.53M$ 15.75M$ 9.72M
Diluted Average Shares
$ 90.57M$ 22.35M$ 21.78M$ 20.53M$ 15.75M$ 9.72M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 141.11M$ 140.33M$ 138.54M$ 109.50M$ 78.31M$ 28.11M
Net Income From Continuing And Discontinued Operation
$ -109.37M$ -110.82M$ -128.48M$ -105.15M$ -75.66M$ -20.00M
Normalized Income
$ -94.12M$ -98.20M$ -128.48M$ -105.15M$ -75.58M$ -19.90M
Interest Expense
$ 5.27M$ 57.00K----
$ -94.55M$ -92.29M$ -126.74M$ -109.48M$ -77.18M$ -19.95M
$ -92.73M$ -90.52M$ -124.69M$ -108.15M$ -76.76M$ -19.74M
Currency in USD

Urogen Pharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis